Patent intelligence · US
US 8536165
Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
Patent details — US 8536165
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 17, 2013
- Expiration
- Sep 12, 2033
- Applicant
- Almirall, S.A.
- Claims
- 24
- CPC classes
- A61K, A61K31/44, A61K31/444, A61K31/4545
Quick answer
US 8536165 (Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors) is held by Almirall, S.A.. Status: granted. Granted Sep 17, 2013. Expires Sep 12, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Almirall, S.A.
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61K, A61K31/44, A61K31/444, A61K31/4545, A61K31/47, A61K31/505
More from Almirall, S.A.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 8536165?
US 8536165 (Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors) is held by Almirall, S.A.. Status: granted. Granted Sep 17, 2013. Expires Sep 12, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8536165?
Almirall, S.A. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 8536165 expire?
Our index shows an expiration date of Sep 12, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.